Organovo Presents Data Supporting 3D Bioprinted Liver Tissues for Drug Toxicity Testing and Liver Fibrosis Modeling

Organovo Holdings, Inc. (NYSEMKT:ONVO) announced five presentations at the Society of Toxicology’s to demonstrate the broad applicability of Organovo’s exVive3D^TM Human Liver Model for the assessment of drug safety and the detection of multiple clinically-relevant modes of liver injury, including steatosis and fibrosis.
According to Dr. Sharon Presnell, chief technology officer and executive vice president of research & development, Organovo:

Drug-induced liver injury remains a major cause of late-stage clinical failures and market withdrawal, often due to poor translation from preclinical animal studies to clinical outcomes. Organovo’s exVive3D human liver model replicates complex cell-cell interactions and key elements of native tissue architecture to enable the detection of multiple clinically-relevant modes of tissue injury, including necrosis, immune-mediated tissue damage, steatosis, and fibrosis.  When a preclinical or clinical-stage asset presents a challenging safety or efficacy signal, exVive3D provides the unique resolving power of a controlled human tissue microenvironment to investigate mechanism and develop solutions.

Click here to view the full press release.